Am J Gastroenterol 2010; 105:1820–1829 F1 박재현. Background Background A novel mouse line with defects in both transforming growth factor- β type II receptor.

Slides:

Advertisements

Similar presentations

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.

Advertisements

Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Cure’s GTX Licensing Opportunity

Colitis in the Very Young

End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.

Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,

FREEDOMS II TRIAL.

Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.

Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.

1 Benefit-Risk of Crohn’s Disease Therapeutics William Sandborn, MD Mayo Clinic and Mayo College of Medicine Rochester, MN, USA.

“Antibiotics and corticosteroids: Indications and approaches”

Case Presentation 34 y/o male34 y/o male 5 years Crohn’s disease of ileum and Rt. colon5 years Crohn’s disease of ileum and Rt. colon 10 days – Fever,

Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor.

1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % P

TWO DECADES OF USING THE COMBINATION OF TETRACYCLINE DERIVATIVES AND NIACINAMIDE AS STEROID-SPARING AGENTS IN THE MANAGEMENT OF PEMPHIGUS: DEFINING A NICHE.

The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.

Acne Vulgaris: Treatment with Azithromycin Kouzeva V, Hitova M, Dancheva A, Kaliasheva P City Center for Dermatovenerology, Sofia Bulgaria.

Crohn’s Disease & Mycobacterial Infections Kimberly Persley, MD October 19, 2005.

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.

Ruan J et al. Proc ASH 2013;Abstract 247.

You Can Never Stop a Biologic

STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.

Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.

Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,

MIGUEL REGUEIRO, WOLFGANG SCHRAUT, LEONARD BAIDOO, KEVIN E. KIP, ANTONIA R. SEPULVEDA, MARILYN PESCI, JANET HARRISON, SCOTT E. PLEVY GASTROENTEROLOGY 2009;136:441–450.

GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.

R3. 최태웅 / Pf. 김효종 Alimentary Pharmacology & Therapeutics 19 FEB 2016 DOI: /apt.13547

N Engl J Med 2012;367: Dae youn.kim/Prof.Chang hyun Lee.

Learning Objectives Describe the relationship between the JAK-STAT signaling pathway and pathogenesis of inflammatory bowel disease. Summarize the latest.

Cumulative Probability of Developing Colon Cancer in UC Patients

Idelalisib plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a.

Indications of surgery in ulcerative colitis

Presented By Luca Malorni at 2017 ASCO Annual Meeting

1 Patient enrollment flow chart.

The American Heart Association Presented by Dr. Steven E. Nissen

Pseudomonas Infection in Cystic Fibrosis

How the Latest Data in MDD Can Guide Treatment Decisions:

Onderzoek met geneesmiddelen

Case Rep Gastroenterol 2013;7: DOI: /

Goals of Therapy for Patients With UC

Optimizing Use of Biological Agents in Ulcerative Colitis

Abatacept for Crohn's Disease and Ulcerative Colitis

Complicated Cases in Ulcerative Colitis

Pathways in Managing Ulcerative Colitis

Laura Rosenberg, Kavinderjit S

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Illustrations in Ulcerative Colitis

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Pulmonary Arterial Hypertension and Connective Tissue Disease

Methotrexate for Ulcerative Colitis: To Use or Not to Use?

Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study William J. Sandborn, William F. Stenson,

Signal Conditioning.

Volume 149, Issue 7, Pages e2 (December 2015)

Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis Gary R. Lichtenstein,

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Volume 384, Issue 9940, Pages (July 2014)

Issue Highlights Clinical Gastroenterology and Hepatology

This Month in Gastroenterology

Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis Robert D Odze, Francis A Farraye, Jonathan.

Presentation data from US VICTORY Consortium

Presentation data from US VICTORY Consortium

Volume 134, Issue 3, Pages (March 2008)

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.

Treatment Advances for RA

Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.

Authors: Sunil Verma Date posted: December 22, 2008

Endoscopic picture of ulcerative colitis with (A) Mayo grade 3 score with friable mucosa and large ulcers. Endoscopic picture of ulcerative colitis with.

Presentation transcript:

Am J Gastroenterol 2010; 105:1820–1829 F1 박재현

Background Background A novel mouse line with defects in both transforming growth factor- β type II receptor and interleukin-10 receptor 2 signaling, as well as the T-bet – / – / RAG2 – / – mouse model, rapidly and reproducibly developed a disease resembling severe fulminant human ulcerative colitis. -> completely inhibited by a combination of broad-spectrum antibiotics In 2002, Fusobacterium varium was reported to be present in the colonic mucosa of a high proportion (84 % ) of UC patients. Butyric acid, a product of F. varium culture supernatants, was also shown to cause UC-like lesions in mice.

Methods(1) Methods(1)

Methods(2) Methods(2) Primary endpoint : clinical response documented by the Mayo score at 3 months after treatment completion Secondary endpoint : clinical and endoscopic score improvements at 12 months

Results

Conclusion Conclusion The 2-week triple antibiotic therapy produced improvement, remission, and steroid withdrawal in active UC more effectively than a placebo.